Depression Rises the Risk of Hypertension Incidence: Discussing the Link through the Ca2+/cAMP Signalling

Author(s): Leandro B. Bergantin*

Journal Name: Current Hypertension Reviews

Volume 16 , Issue 1 , 2020

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Depression and hypertension are medical problems both with clearly restricted pharmacotherapies, along with a high prevalence around the world. In fact, an intensive discussion in the field is that a dysregulation of the intracellular Ca2+ homeostasis (e.g. excess of intracellular Ca2+) contributes to the pathogenesis of both hypertension and depression. Furthermore, depression rises the risk of hypertension incidence. Indeed, several data support the concept that depression is an independent risk issue for hypertension.

Conclusion: Then, which are the possible cellular mechanisms involved in this link between depression and hypertension? Considering our previous reports about the Ca2+ and cAMP signalling pathways (Ca2+/cAMP signalling), in this review I have discussed the virtual involvement of the Ca2+/cAMP signalling in this link (between depression and hypertension). Then, it is important to consider depression into account during the process of prevention, and treatment, of hypertension.

Keywords: Depression, hypertension, Ca2+/cAMP signaling, prevention, treatment, Ca2+ homeostasis.

Meng L, Chen D, Yang Y, Zheng Y, Hui R. Depression increases the risk of hypertension incidence: A meta-analysis of prospective cohort studies. J Hypertens 2012; 30(5): 842-51.
Bergantin LB. Hypertension, diabetes and neurodegenerative diseases: Is there a clinical link through the Ca2+/cAMP signalling interaction? Curr Hypertens Rev 2019; 15(1): 32-9.
Bergantin LB, Caricati-Neto A. Challenges for the pharmacological treatment of neurological and psychiatric disorders: Implications of the Ca2+/cAMP intracellular signalling interaction. Eur J Pharmacol 2016; 788: 255-60.
Bergantin LB, Caricati-Neto A. Advances for the pharmacotherapy of depression - Presenting the rising star: Ca2+/camp signaling interaction. J Syst Integr Neurosci 2017; 3(3): 1-5.
Miranda-Ferreira R, de Pascual R, Smaili SS, et al. Greater cytosolic and mitochondrial calcium transients in adrenal medullary slices of hypertensive, compared with normotensive rats. Eur J Pharmacol 2010; 636(1-3): 126-36.
Tully PJ, Peters R, Pérès K, Anstey KJ, Tzourio C. Effect of SSRI and calcium channel blockers on depression symptoms and cognitive function in elderly persons treated for hypertension: Three city cohort study. Int Psychogeriatr 2018; 21: 1-10.
Bergantin LB, Souza CF, Ferreira RM, et al. Novel model for “calcium paradox” in sympathetic transmission of smooth muscles: Role of cyclic AMP pathway. Cell Calcium 2013; 54(3): 202-12.
Devilliers AS, Russell VA, Carsters ME, et al. Noradrenergic function and hypothalamic-pituitary-adrenal axis activity in primary major depressive disorder. Psychiatry Res 1987; 22(2): 127-39.
Lake CR, Pickar D, Zeigler MG, Lipper S, Slater S, Murphy DL. High plasma norepinephrine levels in patients with major affective disorder. Am J Psychiatry 1982; 139(10): 1315-8.
Roy A, Pickar D, Linnoila M, Potter WZ. Plasma norepinephrine levels in affective disorders. Relationship to melancholia. Arch Gen Psychiatry 1985; 42(12): 1181-5.
Cooper SJ, Kelly JG, King DJ. Adrenergic receptors in depression. Effects of electroconvulsive therapy. Br J Psychiatry 1985; 147: 23-9.
Maes M, Meltzer HY, Suy E, Minner B, Calabrese J, Cosyns P. Sleep disorders and anxiety as symptom profiles of sympathoadrenal system hyperactivity in major depression. J Affect Disord 1993; 27(3): 197-207.
Sommer N, Loschmann PA, Northoff GH, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1995; 1: 244-8.
Xiao L, O’Callaghan JP, O’Donnell JM. Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test. J Pharmacol Exp Ther 2011; 338: 641-7.
Douglas WW, Rubin RP. The role of calcium in the secretory response of the adrenal medulla to acetylcholine. J Physiol 1961; 159: 40-57.
Baker PF, Knight DE. Calcium-dependent exocytosis in bovine adrenal medullary cells with leaky plasma membranes. Nature 1978; 276(5688): 620-2.
Kreye VA, Luth JB. Proceedings: Verapamil-induced phasic contractions of the isolated rat vas deferens. Naunyn Schmiedebergs Arch Pharmacol 1975; 287(Suppl.): R43.
French AM, Scott NC. A comparison of the effects of nifedipine and verapamil on rat vas deferens. Br J Pharmacol 1981; 73(2): 321-3.
Moritoki H, Iwamoto T, Kanaya J, Maeshiba Y, Ishida Y, Fukuda H. Verapamil enhances the non-adrenergic twitch response of rat vas deferens. Eur J Pharmacol 1987; 140(1): 75-83.
Caricati-Neto A, Garcia AG, Bergantin LB. Pharmacological implications of the Ca2+/cAMP signaling interaction: From risk for antihypertensive therapy to potential beneficial for neurological and psychiatric disorders. Pharmacol Res Perspect 2015; 3(5): e00181
Larkman AU, Jack JJ. Synaptic plasticity: Hippocampal LTP. Curr Opin Neurobiol 1995; 5(3): 324-34.
Nicoll RA, Malenka RC. Contrasting properties of two forms of long-term potentiation in the hippocampus. Nature 1995; 377(6545): 115-8.
Duman RS. Depression: A case of neuronal life and death? Biol Psychiatry 2004; 56(3): 140-5.
Miranda-Ferreira R, de Pascual R, de Diego AM, et al. Single-vesicle catecholamine release has greater quantal content and faster kinetics in chromaffin cells from hypertensive, as compared with normotensive, rats. J Pharmacol Exp Ther 2008; 324(2): 685-93.
Miranda-Ferreira R, de Pascual R, Caricati-Neto A, Gandia L, Jurkiewicz A, Garcia AG. Role of the endoplasmic reticulum and mitochondria on quantal catecholamine release from chromaffin cells of control and hypertensive rats. J Pharmacol Exp Ther 2009; 329(1): 231-40.
Davison K, Jonas BS, Dixon KE, Markovitz JH. Do depression symptoms predict early hypertension incidence in young adults in the CARDIA study. Arch Intern Med 2000; 160: 1495-500.
Bergantin LB, Caricati-Neto A. Emerging concepts for neuroscience field from Ca2+/cAMP signalling interaction. J Neurol Exp Neurosci 2017; 3(1): 29-32.
Caricati-Neto A, Bergantin LB. Pharmacological modulation of neural Ca2+/camp signaling interaction as therapeutic goal for treatment of Alzheimer’s disease. J Syst Integr Neurosci 2017; 3: 185.
Caricati-Neto A, Bergantin LB. The passion of a scientific discovery: the “calcium paradox” due to Ca2+/camp interaction. J Syst Integr Neurosci 2017; 3: 186.
Caricati-Neto A, Bergantin LB. From a “eureka insight” to a novel potential therapeutic target to treat Parkinson’s disease: The Ca2+/camp signalling interaction. J Syst Integr Neurosci 2017; 4: 187.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 13 February, 2020
Page: [73 - 78]
Pages: 6
DOI: 10.2174/1573402115666190116095223

Article Metrics

PDF: 22
PRC: 1